Novo Nordisk A/S logo
Novo Nordisk A/S NVO
$ 40.38 -1.05%

Annual report 2025
added 04-04-2026

report update icon

Novo Nordisk A/S Gross Profit 2011-2026 | NVO

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Novo Nordisk A/S

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
250 B 246 B 196 B 149 B 117 B 106 B 102 B 94.2 B 94.1 B 94.6 B 91.7 B 74.2 B 69.4 B 64.6 B 53.8 B

All numbers in DKK currency

Indicator range from annual reports

Maximum Minimum Average
250 B 53.8 B 120 B

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
2.32 M - - $ 86.2 M usaUSA
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
177 K $ 3.85 3.22 % $ 9.26 B australiaAustralia
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
195 M $ 327.75 -1.69 % $ 42.9 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
5.51 M - 2.54 % $ 160 B franceFrance
Aligos Therapeutics Aligos Therapeutics
ALGS
-10.5 M $ 7.65 3.1 % $ 75.6 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
90 K - - $ 7.46 M israelIsrael
Cabaletta Bio Cabaletta Bio
CABA
0.006 $ 3.44 1.03 % $ 346 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
Aptinyx Aptinyx
APTX
1.56 K - -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
5.68 K - -13.39 % $ 1.45 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
356 M $ 21.62 -0.28 % $ 1.01 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Advaxis Advaxis
ADXS
90 K - -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
2.65 M - 5.93 % $ 314 M canadaCanada
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
2.03 M $ 3.1 -4.32 % $ 5.1 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
102 K - -10.17 % $ 12.2 K usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
190 M $ 1.41 -9.03 % $ 363 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
32.9 M $ 4.18 -1.5 % $ 447 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
10 K - 1.93 % $ 17.4 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
14 M - -4.8 % $ 255 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
2.79 B $ 8.68 -0.12 % $ 6.83 B spainSpain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
4.67 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
1.07 - - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
4.15 M - -16.75 % $ 25.8 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
5.48 M $ 33.44 -1.27 % $ 2.22 B usaUSA
bluebird bio bluebird bio
BLUE
-4.03 M - - $ 546 M usaUSA